



## **Silence Therapeutics plc**

### **Notification of Results**

**London, UK, 28 April 2010** – Silence Therapeutics plc (AIM: SLN) (“Silence” or the “Company”) announces that it will be releasing its preliminary results for the year ended 31 December 2009 on Thursday, 29 April 2010.

**Analyst Conference Call and Webcast:** An analyst briefing call and simultaneous webcast will be held Thursday, 29 April 2010 at 2:00pm GMT / 9:00am ET. The webcast can be accessed via Silence Therapeutics' website at [www.silence-therapeutics.com](http://www.silence-therapeutics.com). The conference call can be accessed by dialing:

**U.K.: 0 808 101 7548**

**U.S.: 913-312-1483**

**Participant PIN code: 6504213**

The archived webcast will be available afterwards on Silence Therapeutics' website.

#### **About Silence Therapeutics plc ([www.silence-therapeutics.com](http://www.silence-therapeutics.com))**

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. A second, complementary delivery technology known as PolyTran™ uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration. Additionally, the company has a platform of novel short interfering RNA (siRNA) molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets. The company's strong and diverse intellectual property portfolio includes exclusive licenses from the University of Massachusetts on three patent families associated with the Zamore “Design Rules,” which cover broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research activities in Berlin and operations in Palo Alto, CA.

**Forward-Looking Statements**

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

###

**For further information, please contact:**

**Silence Therapeutics  
Silence)**

Phil Haworth, CEO  
(650) 855-1514  
[p.haworth@silence-therapeutics.com](mailto:p.haworth@silence-therapeutics.com)

**Vida Communication (on behalf of**

Tim Brons (media)  
(415) 675-7400  
[tbrons@vidacommunication.com](mailto:tbrons@vidacommunication.com)

**Nomura Code Securities**

Richard Potts / Jonathan Senior  
020 7776 1200

Stephanie Diaz (investors)  
(415) 675-7400  
[sdiaz@vidacommunication.com](mailto:sdiaz@vidacommunication.com)